The Food and Drug Administration approves Dacogen injections for the treatment of myelodysplastic syndromes (MDS).

People with MDS have bone marrow that does not produce enough mature blood cells, resulting in a lack of healthy blood cells that can function properly in the body

The Food and Drug Administration on Wednesday approved an injectable drug in the treatment of a rare group of bone marrow diseases that are often fatal.

The FDA said Dacogen would give another treatment option to people suffering from myelodysplastic syndromes, a condition in which bone marrow does not produce an adequate amount of mature blood cells